Training Program in Personalized Cardiovascular Medicine (TPIPCVM)

个性化心血管医学培训计划 (TPIPCVM)

基本信息

  • 批准号:
    10454147
  • 负责人:
  • 金额:
    $ 40.29万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-07-01 至 2024-06-30
  • 项目状态:
    已结题

项目摘要

TRAINING IN PERSONALIZED CARDIOVASCULAR MEDICINE (TPIPCVM) Project Summary Cardiovascular disease (CVD) remains a major cause for significant morbidity and mortality in the U.S. especially in ethnic minorities with their high burden of risk factors. Personalized medicine is a rapidly growing field of healthcare whereby an individual's unique genomic, environmental and clinical background is analyzed to ascertain susceptibility to disease, predict their clinical course and tailor specific therapies. Despite recent advances in CV genomics, our inability to target therapy to underlying mechanisms in individual patients, the failure to translate these scientific discoveries to the bedside care of patients and barriers to the incorporation of ethnic minorities in translational CV research have limited our ability to fulfill the promise of personalized medicine. Furthermore, traditional training programs are no longer able to provide trainees with the requisite skills needed to implement the personalized medicine revolution underway. Thereby, major goals of the Training Program in Personalized Cardiovascular Medicine (TPIPCVM) are to equip trainees to become leaders in CV Genomics and be trained in molecular, cellular, disease and whole animal modeling and clinical and translational approaches to CVD so that this new knowledge can be translated into best evidence-based personalized CV care. We will recruit highly talented and motivated pre- and post-doctoral trainees and provide them with the highest caliber training in CV genomics stemming from existing strengths of our faculty in the Division of Cardiology and our partners at UIC. The 3 Research Focus Groups: 1) Cardiac arrhythmias; 2) Ischemic and non-ischemic cardiomyopathy; and CVD-related metabolic syndrome are highly interrelated with each other and directly linked with the central theme of Personalized CV Genomics. The overarching goal of the TPIPCVM is to train the next generation of CV investigators to create new knowledge and implement into best evidence-based personalized medicine. The TPIPCVM mentors are highly successful physician-scientists/scientists with a proven record of research, mentoring and collaboration who offer superb inter- and multi- disciplinary training opportunities. Major strengths of this training program include: exposure of trainees to an integrated basic science molecular, cellular, and whole patient approach to identify the underlying mechanisms of CVD; the track record of the faculty and their common research interest in Personalized CV Genomics; dedicated training in personalized CV medicine; and the potential to implement scientific discoveries to a diverse and under-represented population of patients cared for at UIC Medical Center. The TPIPCVM sets out to train 2 pre-doctoral and 2 post-doctoral students annually. Collectively, this Training Program offers a unique training experience and fulfills an urgent need for training in personalized CV medicine.
个性化心血管医学培训(TPIPCVM) 项目摘要 心血管疾病(CVD)仍然是导致明显发病率和死亡率的主要原因 美国,尤其是在少数民族中,其危险因素负担很高。个性化药物是 迅速发展的医疗领域,个人的独特基因组,环境和临床 分析背景以确定对疾病的敏感性,预测其临床过程并量身定制 具体疗法。尽管CV基因组学最近取得了进步,但我们无法将治疗靶向 个别患者的基本机制,未能将这些科学发现转化为 患者的床旁护理和限制少数民族在转化简历中的障碍 研究限制了我们实现个性化医学承诺的能力。此外, 传统培训计划不再能够为受训者提供所需的必要技能 实施个性化医学革命。因此,培训的主要目标 个性化心血管医学(TPIPCVM)的计划将装备学员成为 CV基因组学领导者接受分子,细胞,疾病和整个动物建模的训练 以及CVD的临床和翻译方法,以便将这些新知识转化为 最佳基于证据的个性化简历护理。我们将招募有才华和积极进取的前和动机 博士后学员,并为他们提供CV基因组学中最高的口径培训 从我们在心脏病学系和UIC的合作伙伴的现有优势中。 3 研究焦点小组:1)心律不齐; 2)缺血性和非缺血性心肌病;和 与CVD相关的代谢综合征相互关联,并直接与 个性化简历基因组学的中心主题。 TPIPCVM的总体目标是训练 下一代简历调查人员创建新知识并实施最佳证据 个性化医学。 TPIPCVM导师是非常成功的医师科学家/科学家 凭借可靠的研究记录,指导和协作,他们提供了极好的间和多种 纪律培训机会。该培训计划的主要优势包括:暴露 综合基础科学分子,细胞和整个患者方法的学员,以识别 CVD的基本机制;教师的往绩及其对 个性化的简历基因组学;个性化简历医学的专门培训;以及潜力 实施科学发现,以对照顾AT的各种和代表性不足的患者人群 UIC医疗中心。 TPIPCVM着手训练2个前博士和2名博士后学生 每年。总的来说,该培训计划提供了独特的培训经验,并实现了紧急的 需要培训个性化简历医学。

项目成果

期刊论文数量(20)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Nicotinamide restores tissue NAD+ and improves survival in rodent models of cardiac arrest.
  • DOI:
    10.1371/journal.pone.0291598
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
  • 通讯作者:
Trained immunity of alveolar macrophages enhances injury resolution via KLF4-MERTK-mediated efferocytosis.
Mutant ANP induces mitochondrial and ion channel remodeling in a human iPSC-derived atrial fibrillation model.
  • DOI:
    10.1172/jci.insight.155640
  • 发表时间:
    2022-04-08
  • 期刊:
  • 影响因子:
    8
  • 作者:
    Ly, Olivia T.;Chen, Hanna;Brown, Grace E.;Hong, Liang;Wang, Xinge;Han, Yong Duk;Pavel, Mahmud Arif;Sridhar, Arvind;Maienschein-Cline, Mark;Chalazan, Brandon;Ong, Sang-Ging;Abdelhady, Khaled;Massad, Malek;Rizkallah, Lona Ernst;Rehman, Jalees;Khetani, Salman R.;Darbar, Dawood
  • 通讯作者:
    Darbar, Dawood
Atrial Fibrillation in Inherited Channelopathies.
  • DOI:
    10.1016/j.ccep.2020.10.004
  • 发表时间:
    2021-03
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Al-Azaam, Baha'a;Darbar, Dawood
  • 通讯作者:
    Darbar, Dawood
Coronary arterial vasculature in the pathophysiology of hypertrophic cardiomyopathy.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Dawood Darbar其他文献

Dawood Darbar的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Dawood Darbar', 18)}}的其他基金

Genotype-guided therapy for atrial fibrillation
心房颤动的基因型引导治疗
  • 批准号:
    10671651
  • 财政年份:
    2020
  • 资助金额:
    $ 40.29万
  • 项目类别:
Genotype-guided therapy for atrial fibrillation
心房颤动的基因型引导治疗
  • 批准号:
    10453452
  • 财政年份:
    2020
  • 资助金额:
    $ 40.29万
  • 项目类别:
Human iPSC-derived atrial cardiomyocytes to model atrial fibrillation in a dish
人 iPSC 衍生的心房心肌细胞在培养皿中模拟心房颤动
  • 批准号:
    10549330
  • 财政年份:
    2020
  • 资助金额:
    $ 40.29万
  • 项目类别:
Human iPSC-derived atrial cardiomyocytes to model atrial fibrillation in a dish
人 iPSC 衍生的心房心肌细胞在培养皿中模拟心房颤动
  • 批准号:
    10548469
  • 财政年份:
    2020
  • 资助金额:
    $ 40.29万
  • 项目类别:
Genotype-guided therapy for atrial fibrillation
心房颤动的基因型引导治疗
  • 批准号:
    10215617
  • 财政年份:
    2020
  • 资助金额:
    $ 40.29万
  • 项目类别:
Obesity-Mediated Atrial Fibrillation: Underlying Mechanisms and Responsiveness to Antiarrhythmic Therapy
肥胖介导的心房颤动:潜在机制和抗心律失常治疗的反应
  • 批准号:
    10477286
  • 财政年份:
    2019
  • 资助金额:
    $ 40.29万
  • 项目类别:
Obesity-Mediated Atrial Fibrillation: Underlying Mechanisms and Responsiveness to Antiarrhythmic Therapy
肥胖介导的心房颤动:潜在机制和抗心律失常治疗的反应
  • 批准号:
    10266061
  • 财政年份:
    2019
  • 资助金额:
    $ 40.29万
  • 项目类别:
Obesity-Mediated Atrial Fibrillation: Underlying Mechanisms and Responsiveness to Antiarrhythmic Therapy
肥胖介导的心房颤动:潜在机制和抗心律失常治疗的反应
  • 批准号:
    9974275
  • 财政年份:
    2019
  • 资助金额:
    $ 40.29万
  • 项目类别:
Obesity-Mediated Atrial Fibrillation: Underlying Mechanisms and Responsiveness to Antiarrhythmic Therapy
肥胖介导的心房颤动:潜在机制和抗心律失常治疗的反应
  • 批准号:
    10905978
  • 财政年份:
    2019
  • 资助金额:
    $ 40.29万
  • 项目类别:
Training Program in Personalized Cardiovascular Medicine (TPIPCVM)
个性化心血管医学培训计划 (TPIPCVM)
  • 批准号:
    10204788
  • 财政年份:
    2018
  • 资助金额:
    $ 40.29万
  • 项目类别:

相似国自然基金

基于医保战略性购买的国家药品价格谈判政策因果效应、长效机制及优化策略研究
  • 批准号:
    72374167
  • 批准年份:
    2023
  • 资助金额:
    40 万元
  • 项目类别:
    面上项目
药品网上零售即时配送的时空协同优化方法研究
  • 批准号:
    72371044
  • 批准年份:
    2023
  • 资助金额:
    41 万元
  • 项目类别:
    面上项目
天然水体中药品和个人护理品间接光降解产物预测模型的构建和应用
  • 批准号:
    42307496
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
复杂网络视角下互联网药品销售安全风险识别、度量及协同治理研究
  • 批准号:
    72304280
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
国家药品带量采购政策实施效果评价及影响因素分析研究
  • 批准号:
    72304006
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

University of Louisville Biomedical Integrative Opportunity for Mentored Experience Development -PREP (UL-BIOMED-PREP)
路易斯维尔大学生物医学综合指导经验开发机会 -PREP (UL-BIOMED-PREP)
  • 批准号:
    10557638
  • 财政年份:
    2023
  • 资助金额:
    $ 40.29万
  • 项目类别:
Mindfulness and Behavior Change to Reduce Cardiovascular Disease Risk in Older People with HIV
正念和行为改变可降低老年艾滋病毒感染者的心血管疾病风险
  • 批准号:
    10762220
  • 财政年份:
    2023
  • 资助金额:
    $ 40.29万
  • 项目类别:
Elucidating the Role of Microenvironment Mechanics in Regulating Cardiac Myofibroblast Plasticity
阐明微环境力学在调节心脏肌成纤维细胞可塑性中的作用
  • 批准号:
    10570135
  • 财政年份:
    2023
  • 资助金额:
    $ 40.29万
  • 项目类别:
Advancing Student Potential for Inclusion with Research Experiences (ASPIRE)
通过研究经验提升学生融入的潜力(ASPIRE)
  • 批准号:
    10678356
  • 财政年份:
    2023
  • 资助金额:
    $ 40.29万
  • 项目类别:
Translational Research and Implementation Science for Nurses (TRAIN) Program 2.0
护士转化研究和实施科学 (TRAIN) 计划 2.0
  • 批准号:
    10680769
  • 财政年份:
    2023
  • 资助金额:
    $ 40.29万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了